Sam Brusco, Associate Editor12.07.23
Edwards Lifesciences announced a plan to spin off its critical care business by the end of 2024.
The company said spinning off the business will help sharpen its focus on transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and Surgical technologies—as well as make new investments in interventional heart failure technologies.
“We expect our sharpened focus in structural heart to drive sustainable growth in the years to come as we embark on a new era of innovation to address large unmet patient needs,” Bernard Zovighian, Edwards’ CEO, told the press. “I’m pleased with our performance in 2023 as we have reinforced our TAVR leadership position with new clinical evidence and reached an inflection point with new approved mitral and tricuspid technologies. In 2024, we are projecting strong sales growth and look forward to launching breakthrough technologies and progressing on multiple important clinical trials.”
The company is having its annual investor conference today and will discuss milestones including:
The company said spinning off the business will help sharpen its focus on transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and Surgical technologies—as well as make new investments in interventional heart failure technologies.
“We expect our sharpened focus in structural heart to drive sustainable growth in the years to come as we embark on a new era of innovation to address large unmet patient needs,” Bernard Zovighian, Edwards’ CEO, told the press. “I’m pleased with our performance in 2023 as we have reinforced our TAVR leadership position with new clinical evidence and reached an inflection point with new approved mitral and tricuspid technologies. In 2024, we are projecting strong sales growth and look forward to launching breakthrough technologies and progressing on multiple important clinical trials.”
The company is having its annual investor conference today and will discuss milestones including:
- Early completion of enrollment in the PROGRESS pivotal trial studying moderate aortic stenosis (AS) patients, in early 2024
- Data from the EARLY TAVR pivotal trial studying severe asymptomatic AS patients, at TCT 2024
- Commercializing the EVOQUE tricuspid valve in Europe and expecting U.S. approval mid-2024